Korean J Blood Transfus.  2014 Aug;25(2):160-164. 10.0000/kjbt.2014.25.2.160.

The First Case of Anti-f(ce) and Anti-Csa Antibodies in Korea

Affiliations
  • 1Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. swkwon@amc.seoul.kr

Abstract

Anti-f(ce) has been associated with hemolytic transfusion reaction (HTR) and hemolytic disease of the fetus and newborn (HDFN), however, anti-Cs(a) has not been associated with red blood cell (RBC) destruction. Although anti-Cs(a) has clinical insignificance as a high-titer low-avidity (HTLA) antibody, this antibody can cause confusion in interpreting an antibody identification test, particularly coexistence of a clinically significant antibody. A 65-year-old woman with liver metastases of Klatskin tumors and cholangitis was admitted to the hospital for abdominal pain. She developed hematochezia on hospital day 10. She was at the status of active bleeding and required transfusion. The result of antibody identification test was warm-reactive autoantibody and unidentifiable alloantibody, therefore, the least incompatible packed RBCs had to be transfused to the patient. No hemolytic transfusion reaction occurred and hemoglobin level was normalized. Thereafter, anti-f(ce) and anti-Cs(a) antibodies were identified in the patient's serum. To the best of our knowledge, this is the first report of anti-f and anti-Cs(a) antibodies in Korea.

Keyword

Anti-f(ce) antibody; Anti-Cs(a) antibody; Antibody screening test

MeSH Terms

Abdominal Pain
Aged
Antibodies*
Blood Group Incompatibility
Cholangitis
Erythrocytes
Female
Fetus
Gastrointestinal Hemorrhage
Hemorrhage
Humans
Infant, Newborn
Klatskin's Tumor
Korea
Liver
Neoplasm Metastasis
Antibodies
Full Text Links
  • KJBT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr